Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 2, 2010 Brian Orelli	Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today.
Scientific American September 2009 Melinda Wenner	Gene therapy: An Interview with an Unfortunate Pioneer Lessons learned by James M. Wilson, the scientist behind the first gene therapy death
HHMI Bulletin Aug 2011	Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response.
The Motley Fool June 4, 2007 Brian Lawler	Is Introgen Stringing Investors Along? Investors, this is one development-stage drugmaker not to own.
BusinessWeek March 6, 2006 Bruce Einhorn	A Cancer Treatment You Can't Get Here China, with lower regulatory hurdles, is racing to a lead in gene therapy.
BusinessWeek April 22, 2010 Rob Waters	Gene Therapy Takes a Turn for the Better Researchers and investors are heartened by advances in gene therapy. Analysts say revenues are still several years off, however.
The Motley Fool May 21, 2007 Mike Havrilla	Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
Scientific American July 2008 Christine Soares	Looking at Yesterday's Genes for Tomorrow's Cures Resurrected "jumping gene" could deliver DNA.
Chemistry World August 31, 2011 Hayley Birch	Smallpox vaccine virus puts cancer in its sights The results of a human cancer therapy trial show for the first time that tumors can be targeted and infected by engineered viruses, without damage to surrounding tissues.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.
Fast Company December 2009 Elizabeth Svoboda	Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
Salon.com June 1, 2000 Tabitha M. Powledge	Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool October 16, 2007 Brian Orelli	Pozen Hedges Its Bets As promised, Pozen and partner GlaxoSmithKline announce that the pair have submitted a response to their approvable letter for Trexima, and that they plan to do an additional just-in-case safety trial.
BusinessWeek February 10, 2011 Rob Waters	Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
Chemistry World March 30, 2006 Helen Carmichael	Gene Therapists Swarm Round Honeycomb Lipid Researchers have synthesised a lipid molecule they say shows real promise in gene therapy. The lipid forms a novel honeycomb complex that the researchers claim is tailored to non-viral DNA delivery.
The Motley Fool March 31, 2011 Brian Orelli	Better Buy? Seattle Genetics or ImmunoGen Battle of the heat-seeking cellular missiles.
Wired September 2002 Amanda Griscom	Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science.
Pharmaceutical Executive June 1, 2007	Thoughtleader: Stephen Sherwin, Cell Genesys Cell Genesys has been able to raise enough capital to gamble on what it CEO believes could be the future's most promising therapies, including gene activation, immunotherapy, and oncolytic virus therapy.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool October 12, 2010 Travis Hoium	Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Chemistry World October 14, 2011 James Mitchell Crow	Twist in the tale to improve gene therapy New insights into the physical properties of different forms of DNA could help to improve gene therapy, chemists in Spain and India say.
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool October 22, 2010 Luke Timmerman	Aastrom Maps Out Pivotal Trial Strategy With Adult Stem Cell Therapy Aastrom needs a good strategy for working with U.S. drug regulators.
Chemistry World February 24, 2010 James Urquhart	Buckyball-based gene delivery Japanese researchers have demonstrated effective gene delivery in mice using carbon buckyballs.
Chemistry World June 12, 2012 Nina Notman	Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
The Motley Fool August 9, 2010 Luke Timmerman	Kaleetan Seeks to Stand on Dendreon's Shoulders Kaleetan Pharmaceuticals tries to improve upon Dendreon's breakthrough cancer drug.
The Motley Fool July 25, 2007 Brian Orelli	On to the FDA With a New Name After four phase 3 clinical trials, Advanced Magnetics is ready to submit a New Drug Application for ferumoxytol, and if all goes well, could have the product on the market by the end of next year.
Chemistry World August 8, 2012	Protein Coat for Gene Therapy Kenneth Woycechowsky's group at the University of Utah has modified a non-viral protein so that it will carry RNA.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
Chemistry World September 26, 2006 Fiona Case	Synchronised Delivery for DNA and Drugs Polymer capsules that can simultaneously deliver drug molecules and DNA into a cell could boost the power of cancer treatments.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
IEEE Spectrum August 2006 Schoenbach et al.	Zap Extreme voltage could be a surprisingly delicate tool in the fight against cancer. The list of effects that scientists have achieved using nanoseconds-long pulses is growing rapidly, though their actual use as a medical treatment is still years away.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
Reason April 2007 Ronald Bailey	Testing Your Strength The World Anti-Doping Agency is developing tests for a form of cheating that doesn't exist yet. The agency banned gene doping, the alteration of genes to enhance athletic performance.
Chemistry World April 2006 Karen Harries-Rees	Editorial: Drugs Testing on Trial A drugs trial in the UK that went disastrously wrong last month has raised questions about the ethics of using paid volunteers in clinical trials and the usefulness of animal testing.
The Motley Fool October 12, 2010 Brian Orelli	Clinical Trial Positive! Shares Just Barely A story about expectations. Seattle Genetics is two for two in recent weeks.
The Motley Fool May 21, 2007 Mike Havrilla	Novel Developments at Neose Neose could have positive clinical trial results in the near future. For a micro-cap biotech stock, Neose has impressive institutional ownership, exceeding 50% of all shares.
The Motley Fool June 2, 2004 Brian Gorman	New Injection for Genzyme A partnership with Medtronic bolsters Genzyme's myoblast cell therapy program.